

Lightning talk abstracts

Precision and mechanistic oncology

Exploration of predictive biomarkers for BCL3 inhibitor treatment response in advanced prostate cancer

Marcos Quintela-Vazquez¹, Tabitha Cunliffe¹, Daniel J Turnham^{1,2}, Anna E Richards¹, Wytske van Weerden³, Robert Jones⁴, Andrew D Westwell⁵, Richard Clarkson¹, Helen B Pearson¹

1. European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University
2. School of Applied Sciences, University of the West England (UWE) Bristol
3. Experimental Oncology, Erasmus University Rotterdam
4. School of Medicine, Cardiff University. 5. School of Pharmacy, Cardiff University

Immuno-oncology

An adenovirus-based 5T4-expressing cancer vaccine induces inflationary CD8+ T cell responses that afford protection from colorectal cancer

Dr Marta Williams¹, Dr Sandra Dimonte¹, Morgan Marsden¹, Lucy Chapman¹, Dr Evelina Statkute², Prof Andrew Godkin¹, Prof Richard J Stanton¹, Prof Awen Gallimore¹, Prof Ian R Humphreys¹

1. Cardiff University
2. Oxford Biomedica

Radiotherapy

Development of a Normal Tissue Complication Probability Model for Dysphagia in PATHOS trial patients

Emma Higgins¹, Richard Webster¹, Nachi Palaniappan¹, Chris Hurt², Zohal Nabi³, Kostas Rizos³, Riki Lad³, Kate Elliott³, Elizabeth Miles³, Joanne Patterson⁴, Kate Hutcheson⁵, Joanne Canham², Lizette Nixon², Christie Heiberg², Matt Beasley⁶, Jones T⁷, Evans M^{1,8}

1. Velindre Cancer Centre, Directorate of Medicine, Cardiff, United Kingdom
2. Centre for Trials Research, Cardiff University, Cardiff, UK
3. National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, UK
4. School of Health Sciences, University of Liverpool, Liverpool, United Kingdom
5. Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
6. University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Bristol, UK
7. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom
8. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom

Cancer clinical trials

Dendrimer-Nanoparticle (DEP) Delivery of Cabazitaxel (DEP-Cabazitaxel): a first-in-human Phase 1/2 Trial in Patients With Advanced Solid Tumors

Karam Aboud, MBChB¹, David J. Pinato, MD, PhD^{2,3}, Martin D. Forster, MBBS, PhD⁴, Anthony M. Joshua, MBBS, PhD⁵, James Korolewicz, MBBS^{2,6}, Cienne Morton, MBBS⁸, Jia Liu, MD PhD⁵, Rasha Cosman, MBBS⁵, Nicola J. Main, BPharm⁷, Julia Le Meur, MSc⁷, Jeremy R.A. Paull, PhD⁷, Stephanie R. Edmondson, PhD⁷, James Spicer, FRCP, PhD⁸, Robert H. Jones, MBBS, PhD¹

1. Velindre Cancer Centre and Cardiff University, Cardiff, UK
2. Department of Surgery & Cancer, Imperial College London, London, UK
3. Department of Translational Medicine, Division of Oncology, University of Piemonte, Novara, Italy
4. University College London (UCL) Cancer Institute, UCL Hospital NHS Trust, London, UK
5. The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia
6. University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
7. Starpharma Pty Ltd, Abbotsford, VIC, Australia
8. King's College London, Guy's Hospital, London, UK

Palliative and supportive oncology

Fracture Related Hospital Admissions in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Treated with Radium - 223 Dichloride

Ope Gbadegesin¹, Jake Tanguay²

1. FY2 Doctor, Cardiff and Vale University Health Board
2. Consultant Clinical Oncologist, Velindre Cancer Centre

Population health-based cancer prevention and early diagnosis

Changes in the urinary proteome could differentiate between prostate cancer and benign prostatic hyperplasia

Tracy C. Knight¹, Nur Aimi Aliah Zainurin¹, Russell Morphew¹, Edward Hughes¹, David Rooke², Stephen F. Hughes³, Iqbal Shergill⁴, NS Luis A. J. Mur¹

1. Department of Life Sciences, Aberystwyth University
2. ProTEM Services Ltd
3. Maelor Academic Unit of Medical and Surgical Sciences, Gwenfro Buildings, Wrexham
4. The Alan de Bolla Wrexham Urology Unit at Wrexham Maelor Hospital, Wrexham

Poster abstracts

Precision and mechanistic oncology

Unveiling the heterogeneity of pancreatic cancer initiation: a novel perspective on normal-mutant cell-cell interactions

Ella Reed¹, Catherine Hogan¹, Beatriz Salvador-Barbero¹

1. ECSCRI, School of Biosciences, Cardiff University, Cardiff, UK

Understanding the functional importance of the Wnt receptor FZD7 in prostate tumourigenesis

Jessica Hembrough¹, Kieran Hodson¹, Toby Pheffe¹, Helen Pearson¹

1. European Cancer Stem Cell Research Institute, Cardiff University

Developing Small Molecule Inhibitors of GATA2: a novel approach to target leukaemia blasts and stem cells in therapy-resistant acute myeloid leukaemia

Rebekah Clarke^{1,3}, Neil Rodrigues², Gui Feng², Marcella Bassetto³, Salvatore Ferla¹

1. Medical School, Pharmacy, Grove Building, Swansea University, SA2 8PP
2. European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Maindy Rd, Hadyn Ellis Building, Cardiff CF24 4HQ
3. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB

Targeting The WNT Ligand Receptor Complex in Cholangiocarcinoma and Prostate Cancer: Therapeutic Potential of FZD7-ADC and WNT974 in Metastatic Disease

Kieran Hodson¹, Hector Arredondo², Valerie Meniel¹, Aled Clayton³, Toby J Pheffe¹

1. Cardiff University School of Bioscience, European Cancer Stem Cell Research Institute
2. The University Of Sheffield, The Mellanby Centre for Musculoskeletal
3. Cardiff University, School of Medicine

OmicsChart: Multi-Omics Cancer Biomarker Discovery for Translational Researchers

Asta Vasalauskaite¹, Tatsiana Aneichyk¹

1. OmicsChart Tech Ltd

Developing and evaluating a virtual laboratory to support medical student oncology education

Karen R Reed¹, Owen J Crawford², Hannah D West¹, Joseph Lewis³, Michael Hackman², Andreia de Almeida¹, Andrew Hilbourne², Emma Short⁴, Sarju Patel¹, Keith Hart¹, Athanasios Hassoulas¹

1. Centre for Medical Education, School of Medicine, Cardiff University, Cardiff, CF14 4YU, UK
2. Cardiff Learning & Teaching Academy, Cardiff University, Cardiff CF10 3AT, UK
3. Department of Cellular Pathology, University Hospital of Wales, Cardiff, CF14 4WX, UK
4. Swansea Bay University Health Board, Morriston Hospital, Swansea, SA6 6NL

Cancer Chemotherapy Curability is Determined by On Going Developmental Epigenetic Processes

Philip Savage¹

1. Dept of Medical Oncology, Cardiff University

Discovery of first-in-class BCL3-p50 protein-protein interaction inhibitor for the treatment of advanced-stage breast cancer

Dusan Ruzic¹, Carwyn Hughes², Arwyn Jones¹, Richard Clarkson², Andrea Brancale³, Andrew Westwell¹

1. Cardiff University, School of Pharmacy and Pharmaceutical Sciences, Cardiff, Wales, U.K.
2. Cardiff University, European Cancer Stem Cell Research Institute, Cardiff, Wales, U.K.
3. University of Chemistry and Technology, Prague, Czech Republic

Heparin-derived nanocarriers as a precision medicine drug for therapeutic reprogramming of glioblastoma phenotypic states

Vadim Le Joncour¹, Austin D. Evans², Oommen P. Oommen³

1. Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
2. Bioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, 33720 Tampere, Finland.
3. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, United Kingdom.

New Wine in Old Bottles - The Therapeutic Promise of the PARP Inhibitor Rucaparib as an N-WASP Inhibitor for Breast Cancer Metastasis

Rhiannon Yanan Yu¹, Q Ping Dou², Elyas Khan², Wen G. Jiang¹, Tracey A. Martin¹

1. Cardiff University School of Medicine, Cardiff, UK
2. Karmanos Cancer Institute, Wayne State University, Detroit, USA

Utilizing biological experimental data and molecular dynamics for the classification of mutational hotspots through machine learning

James G. Davies¹, Georgina E. Menzies¹

1. School of Biosciences, Cardiff University

Glioblastoma-astrocyte interactions drive tumour progression

Ayesha Begum¹, Suresh Kaushik¹, Mathew Clement², Florian A Siebzehnrub¹

1. European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences
2. Division of Infection and Immunity, Cardiff University School of Medicine

Pharmacological Inhibition of cFLIP Targets Breast Cancer Stem Cells

Rhiannon French¹, Olivia Hayward², Andreia Ribeiro da Silva², Timothy Robinson³, Richard Clarkson²

1. University of Oxford, Sir William Dunn School of Pathology
2. European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences
3. Bristol Medical School (PHS), University of Bristol

Investigating BCL3 as a therapeutic target to treat prostate cancer

Tabitha Cunliffe¹, Marcos Quintela-Vazquez¹, Daniel J. Turnham¹, Boris Shorning¹, Luke Piggott², Robert Jones³, Andrea Brancale⁴, Andrew Westwell⁵, Richard W.E. Clarkson¹, Helen B. Pearson¹

1. ECSCRI, School of Biosciences, Cardiff University.
2. TNA Therapeutics, USA.
3. ECMC Cardiff, University Hospital Wales, Cardiff University.
4. University of Chemistry and Technology, Prague.
5. School of Pharmacy, Cardiff University.

Pharmacological targeting of Bcl3 improves outcomes in models of colorectal cancer

Hannah Smith¹, Huw Morgan¹, Adam Higgins¹, Cleo Bonnet¹, Katie Stott¹, Gillian Seaton¹, Richard Clarkson¹

1. European Cancer Stem Cell Research Institute Cardiff University School of Biosciences Maindy Road Cardiff

From healthy pancreas to tumours: identifying the cancer initiating cells

Beatriz Salvador¹, Daniel Ruiz-Palacios², Justo P Castano², Jen Morton³, Owen Sansom³, Catherine Hogan¹

1. ECSCRI, Cardiff University

2. IMIBIC, Cordoba University
3. CRUK Scotland Institute, Scotland

Concentrative Nucleoside Transporter 1 (hCNT1)/SLC28A1 and Equilibrative Nucleoside Transporter 1 (hENT1)/SLC29A1 in human colon cancer, the clinical and therapeutic considerations

Matthew McKenna¹, Amber Li¹, Lin Ye¹, Tracey Martin¹, Wengou Jiang¹, Rachel Hargest¹

1. Cardiff University

Development and Validation of a Novel Multi-Functional Iron Oxide Nanoparticle for the Targeted Induction of Ferroptosis in Cancer

Darius McPhail¹, James Cronin², Rebecca Wurelly², Rhiannon Beadman², Joel Crane³, Mark Davies¹, Debabrata Tripathy⁴, Richard Yuxiong Su⁴, Andrew Tee¹, Juan Mareque-Rivas³

1. School of Medicine, Cardiff University
2. Swansea University Medical School, Swansea University
3. Department of Chemistry, Swansea University
4. Division of Oral and Maxillofacial Surgery, University of Hong Kong

Impact of Brain-Derived Neurotrophic Factor (BDNF) on Tight Junction (TJ) Proteins and Cell Adhesion and Migration in Breast Cancer: Implications for Brain Metastasis

Milad Eshmela¹, Wen G. Jiang¹, Lin Ye¹, Tracey A. Martin¹

1. CCMRC, Cardiff University School of Medicine, Cardiff, Wales, UK

Artemisinin Modulates Tight Junction Integrity in Breast Cancer Brain Metastasis Through the Wnt/ β -Catenin Pathway

Wenxiao Ji¹, Wen G. Jiang¹, Tracey A. Martin¹

1. Cardiff China Medical Research Collaborative

A Molecular Dynamics Study of Differential Base Excision Repair in Cancer Associated DNA loci by OGG1 Machinery.

Lily James-Knight¹, James Davies¹, Georgina Menzies¹

1. School of Biosciences, Cardiff University, Wales

Long-read transcriptomics of alternatively spliced RNA isoforms in pancreatic ductal adenocarcinomas.

Garan Jones¹, Harsh Bhatt¹, Duncan Baird¹

1. Division of Cancer and Genetics, Cardiff University

Exploring the mechanism and predictability of KRASG12D cell elimination mechanisms in the adult pancreas.

Non Williams¹, Beatriz Salvador-Barbero¹, Maria Secrier², Catherine Hogan¹

1. European Cancer Stem Cell Research Institute, Cardiff University
2. UCL Genetics Institute, University College London

Investigating the predictive value of cancer-associated fibroblasts (CAFs) in prostate cancer

Anna Richards¹, Tegen Hooper¹, Jasmine Owen¹, Leah Officer-Jones², Silvia Cusumano², Michelle Somerville³, Lisa Spary⁴, Awen Gallimore³, John Le Quesne², Helen Pearson¹

1. The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University
2. Cancer Research UK Scotland Institute (CRUK SI), Glasgow
3. School of Medicine, Cardiff University
4. Wales Cancer Bank, University Hospital Wales

A systematic approach to identify charged repurposed therapeutics for affinity-based local drug delivery systems for glioblastoma treatment.

Sabarni Sarker^{1,2}, Christodoulos Theodoulou¹, Benjamin Newland¹

1. School of Pharmacy and Pharmaceutical Sciences, Cardiff University
2. Department of Pharmacy, Jagannath University, Dhaka

Noninvasive Microstructure Reconstruction for Prostate Cancer Using Diffusion MRI: Phantom Validation and Clinical Potential

Yang Yang^{1,2}, Adam Threlfall^{1,3}, Leandro Beltrachini^{1,2}

1. Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University
2. School of Physics and Astronomy, Cardiff University
3. School of Computer Science and Informatics, Cardiff University

Identification of CENPB as a Novel Candidate Therapeutic Targets in Acute Myeloid Leukaemia using Proteomic Analysis of Patient Material

Halawi, MA^{1,2}, Smith, D³, Alanazi, MO^{1,4}, Rizzo, S¹, Hughes, OM¹, Alruwaili, AM^{1,6}, Knapper, S¹, Tonks, A¹, Darley, RL¹

1. Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
2. College of Pharmacy, Jazan University, Jazan, Saudi Arabia
3. Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK
4. College of Applied Medical Science, Shaqra University, Riyadh, Saudi Arabia
5. Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
6. Medical Laboratory Technology Department, College of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia

TRPML1, a novel drug target for broad use in Triple Negative Breast Cancer treatment

Bethany Tattersdill¹

1. Cardiff University

Adaptive therapy treatment: Utilising the evolutionary dynamics between different tumour cell populations for Cancer treatment

Liam Ryall-Friend¹, Noemi Picco¹, Mark Davies²

1. Faculty of Science and Engineering, Swansea University
2. Cardiff University

Incorporating Toxicity Feedback to into Adaptive Cancer Therapy

Mark Davies¹, Joel Brown², Jana Gevertz³, Harsh Jain⁴, Irina Kareva⁵, Eduardo Sontag⁵, Kathleen Wilkie⁶

1. Department of Cancer and Genetics, Cardiff University
2. Department of Integrated Mathematical Oncology, Moffitt Cancer Center
3. Department of Mathematics and Statistics, The College of New Jersey
4. Department of Mathematics and Statistics, University of Minnesota - Duluth
5. Department of Mathematics, Northeastern University
6. Department of Mathematics, Toronto Metropolitan University

Assessing an $\alpha v\beta 6$ integrin selective virus-directed enzyme prodrug therapy (VDEPT) in pre-clinical models of Gastric and Head and Neck cancers

Jaya L Vangara^{1,3}, Luned M Badder¹, Sandeep Berry⁴, Toby J Phesse², Mererid Evans^{1,3}, Alan L Parker¹

1. School of Medicine, Cardiff University
2. European Cancer Stem Cell Research Institute, Cardiff University
3. Velindre Cancer Centre
4. Department of ENT, University Hospital of Wales

Evaluation of PDK1 as a Therapeutic Target in Acute Myeloid Leukaemia: Mitigating ROS-Induced PI3K-AKT Activation

Alruwaili AM^{1,2}, Rizzo S¹, Shahid Ullah¹, Hughes O¹, Flores J¹, Gough F¹, Alanazi MO^{1,3}, Halawi M^{1,4}, Niamh O'Neill¹, Knapper S¹, Darley RL¹, Tonks A¹

1. Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, CF14 4XN, Wales, UK.
2. Medical Laboratory Technology Department, College of Applied Medical Science, Northern Border University, Arar 91431, Saudi Arabia.
3. College of Applied Medical Science, Shaqra University, Shaqra 15572, Saudia Arabia.
4. College of Pharmacy, Jazan University, Jazan 82913, Saudi Arabia.

Examining the clinical impact of telomere length and dysfunction in squamous cell carcinoma of the head and neck (HNSCC)

Ashley Poon-King^{1,2}, Kevin Norris^{1,3}, Paola Foulkes⁴, Sandeep Berry⁵, Mererid Evans^{1,2}, Duncan Baird^{1,3}

1. Department of Cancer and Genetics, School of Medicine, Cardiff University
2. Velindre NHS Trust
3. Telonostix Ltd Biotechnology Services
4. Wales Cancer Biobank, Cardiff University
5. Cardiff and Vale University Health Board

The Wales Cancer Biobank Digital (WCB Digital) project: An All-Wales approach to integrated sample and genomic data access for the cancer research community.

Liz Merrifield¹, Dr. Peter Giles¹, Prof. Richard Clarkson², Prof. Richard Adams², Dr. Lisa Spary², Abigail Macarthur², Sian Morgan³, Dr. Erik Waskiewicz³, Dr. Sophie Shaw³

1. BioResource Data Accelerator, Wales Gene Park, Cardiff University
2. Wales Cancer Biobank, Cardiff University
3. All Wales Medical Genomics Service

Gleason Grading of Prostate Cancer Tissue using novel DRAQ5&Eosin Fluorescent Labels and AI classification algorithms.

Michail Georgios Papachristos¹, David Hywel Thomas², Finni Akinade³, Anna Wilson⁴, Emiliano Spezi⁵, Rachel Errington⁶, Dimitris Parthimos¹

1. School of Medicine, Division of Cancer and Genetics, Cardiff University
2. Consultant Histopathologist, University Hospital of Wales
3. School of Medicine, Cardiff University
4. University of Alabama at Birmingham
5. School of Engineering, Cardiff University
6. Head of School of Medicine, Cardiff University

Identifying signal transducer and activator of transcription 3 as a therapeutic target to block extracellular matrix deposition and tumour growth in Tuberous Sclerosis Complex

Samia S. Alzahrani¹, Jesse D. Champion¹, Darius McPhail¹, Mohammad A. M. Alzahrani¹, Brian L. Calver¹, Elaine Dunlop¹, Mark Davies¹, Andrew R. Tee¹

1. Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Towards Non-invasive Cancer Detection and Grading Through the Characterisation of Tissue Microstructure via Diffusion MRI

Adam Threlfall^{1,2}, Yang Yang^{1,3}, Emiliano Spezi⁴, Derek Jones^{1,5}, Marco Palombo^{1,2}, Leandro Beltrachini^{1,3}

1. CUBRIC, Cardiff University
2. School of Computer Science and Informatics, Cardiff University
3. School of Physics and Astronomy, Cardiff University
4. School of Engineering, Cardiff University
5. School of Psychology, Cardiff University

Long Read Sequencing Technologies and Lung Cancer Liquid Biopsies

Karam Aboud^{1,2}, Joanne Morgan³, Nigel Williams³, Magdalena Meissner^{1,2,4}, Rachel Dodds¹, Sian Morgan¹, Sophie Shaw¹

1. All Wales Medical Genomics Service, Cardiff and Vale University Health Board
2. School of Medicine, Cardiff University
3. Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University
4. Velindre University NHS Trust

Exploring a role for SLC39A zinc transporters in the dissemination of breast cancer cells

Georgia Farr¹, Samuel Jones¹, Kathryn M Taylor¹

1. School of Pharmacy and Pharmaceutical Sciences, Cardiff University

Investigating the role of PREX2 in Prostate Cancer as a new avenue to sensitise to MAPK/PI3K/AKT targeted therapies

Samuel C. Hawkins¹, Boris S. Shorning¹, Wytske Van Weerden², Richard W.E. Clarkson¹, Andrew D. Campbell³, Helen B. Pearson¹

1. The European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK
2. ERASMUS Medical University, Rotterdam
3. Cancer Research UK Scotland Institute, Glasgow, UK

The BioResource Data Accelerator: An all-Wales approach to sample and genomic data access serving both the rare disease and cancer research communities

Liz Merrifield¹, Dr. Peter Giles¹, Dr Andrew Fry¹, Rhys Vaughan¹, Prof. Richard Clarkson², Prof. Richard Adams², Dr. Lisa Spary², Abigail Macarthur², Sian Morgan³, Dr. Joseph Halstead³, Dr Sophie Shaw³, Dr Erik Wasckiewicz³, Joanna Zabkiewicz⁴

1. Wales Gene Park, Cardiff University
2. Wales Cancer Biobank, Cardiff University
3. All Wales Medical Genomics Service
4. Cardiff ECMC, Department of Cancer and Genetics Cardiff University

Telomere dysfunction and fusion in gliomas: defining prognosis and genome instability

Harsh Bhatt^{1,2}, Kevin Norris¹, Kez Cleal¹, Megan Hodgson³, Christopher Herbert⁴, Kathreena M. Kurian⁵, William P. Gray^{2,6}, Duncan M. Baird¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
2. Department of Neurosurgery, University Hospital of Wales, Cardiff, UK
3. School of Medicine, Cardiff University, Cardiff, UK
4. Bristol Haematology and Oncology Centre, University Hospitals Bristol National Health Service (NHS) Foundation Trust, Bristol, UK
5. Brain Tumour Research Centre, Bristol Medical School, Bristol, UK
6. Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit, School of Medicine, Cardiff University, Cardiff, UK

Exploring primary lung cancer resistance using tissue and circulating ctDNA biomarkers

Karam Aboud^{1,2}, Erik Wasckiewicz², Sophie Shaw², Sian Morgan², Rachel Dodds², Rhian White², Kirsty Hambridge², India Tresadern², Rob Jones³, Paul Shaw⁴, Richard Adams⁵, Magda Meissner¹

1. Cardiff University (DCG)
2. All Wales Medical Genomics Lab (AWMGL)
3. Cardiff University (DCG)
4. Velindre Cancer Centre
5. Centre for Trials Research, Cardiff

Validation of ASAH1 as a novel target for Glioblastoma

Loren Waters¹, Saul Michue-Seijas¹

1. Medicines Discovery Institute, Cardiff University

Short and long-distance communication in cancer: Feedback regulation of Ras signalling in tumourigenesis and cachexia

Shijun Fang¹, Silvia Ziliotto¹, Hoi Ping Weeks¹, Jack Bruton¹, Fisun Hamaratoglu¹

1. School of Biosciences, Cardiff University

De-targeting species D Human Adenovirus serotype 10 and enhancing its transduction to cancer cells via fiber modifications.

Mahulena Marušková¹, Emily A Bates¹, Rebecca Bayliss¹, Alan L Parker^{1,2}

1. Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, Wales, UK
2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK

Emerging role of IGF1R in the downregulation of Kidins220-promoted disease progression of pancreatic cancer

Deepa Shankla¹, Qingping Dou², Wen G. Jiang¹, Lin Ye¹

1. Cardiff China Medical Research Collaborative, Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK
2. Barbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA

Loss of bone morphogenetic proteins (BMP) and BMP receptors in gastric cancers is associated with disease progression and poor prognosis

Manal Alamri¹, Yongning Jia², Xiangyu Gao², Ke Ji², Shuqin Jia², Fiona Ruge¹, Wen G. Jiang¹, Lin Ye¹

1. Cardiff China Medical Research Collaborative, Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.
2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Gastrointestinal Tumour Centre, Peking University Cancer Hospital & Institute, Beijing, P.R. China

Immuno-oncology

Re-expression of MHCII in Colorectal Organoids: Investigating the novel role of EHMT1 in regulating MHCII expression

Nahla Elzefzafy¹, Louise Tee¹, Maria Pinna¹, Neeraj Lal¹, Gary Middleton², Andrew Beggs¹

1. Institute of Cancer and Genomics, University of Birmingham
2. Institute of Immunology and Immunotherapy, University of Birmingham

Developing precision adenovirotherapies for glioblastoma

Emily Bates¹, Rebecca Bayliss¹, Mahulena Maruskova¹, Alan Parker¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Localised delivery of chemoattractants and immune checkpoint inhibitors using a precision virotherapy in pancreatic cancer

Charley Lovatt-Travers¹, Luned M. Badder¹, James Davies¹, Catherine Hogan², Alan L Parker¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University
2. European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University

Development of a precision immunovirotherapy expressing a bispecific immune cell engager for treatment of Glioblastoma

Rebecca J Bayliss¹, Courtney Stewart¹, Emily A Bates¹, Alan L Parker¹

1. School of Medicine, Cancer and Genetics Building, University Hospital Wales, Heath Park, Cardiff University, Cardiff CF14 4XN

Developing pseudotyped $\alpha\beta 6$ -integrin targeted adenovirus 5-based vectors for tumour selective virotherapy

Emma A. Swift¹, Rebecca Wallace¹, Emily A. Bates¹, James A. Davies¹, Pierre J. Rizkallah², Alan L. Parker¹

1. Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN
2. Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN

Manipulating T-cell responses to improve anti-GBM immunity

Mathew Clement^{1,2}, Sarah Lauder¹, Michelle Sommerville¹, Awen Gallimore^{1,2}

1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
2. Systems Immunity Research Institute, Cardiff University, Cardiff, UK

Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis

Tessa Watts¹, Judit Cstontos¹, Dominic Roche¹

1. Cardiff University, School of Healthcare Sciences

Novel approaches to reduce immune-related adverse events associated with successful cancer therapy; combined targeting of PI3K δ and the immune checkpoint receptor LAG3.

Sarah N Lauder¹, Lorenzo Capitani¹, Ana Pires¹, Kathryn Smart¹, Michelle Somerville¹, Andrew Godkin¹, Bart Vanhaesebroeck², Awen Gallimore¹

1. Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, CF14 4XN, UK
2. UCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street, London WC1E 6BT, UK

Development and Optimisation of a Patient Derived Organoid Model for T-cell Co-culture of Colorectal Cancer (CRC) in Animal-free Matrices

Chloe Harris¹, Stephanie Burnell¹, Lorenzo Capitani¹, Kasope Wolffs^{1,2}, Fiona Morgan², Paola Foulkes², Andrew Godkin^{1,3}, Awen Gallimore¹

1. Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
2. Wales Cancer Bank, UHW Main Building, Heath Park, Cardiff, CF14 4XN, UK
3. Department of Gastroenterology and Hepatology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK

4. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Knockdown of hnRNPA0 Induces G2/M Arrest and reduces cell growth in acute myeloid leukaemia

Alanazi, MO^{1,2}, Halawi, M^{1,3}, Hughes, OM¹, Rizzo, S¹, Gilkes, AF¹, Yoosuf Aly, Z¹, Alruwaili, AM^{1,4}, Knapper, S⁵, Darley, RL¹, Tonks, A^{1,6}

1. Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
2. College of Applied Medical Science, Shaqra University, Shaqra, Riyadh 15572, Saudi Arabia.
3. College of Pharmacy, Jazan University, Jazan, Saudi Arabia
4. Medical Laboratory Technology Department, College of Applied Medical Sciences, Northern Border University, Arar 91431, Saudi Arabia.
5. Clinical Professor of Haematology, Cardiff Experimental and Cancer Medicine Centre, School of Medicine, Cardiff University, Cardiff, UK
6. Acting Head of Department of Haematology, Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Assessment of a pre-clinical adenoviral vectored cancer immunotherapy designed to harness antiviral immunity against cancer cells

Kate Milward¹, Aimee Lucignoli¹, Katie Topley², Elise Moses¹, Garry Dolton², Lucy C Jones^{2,3}, Andrew Sewell^{2,4}, Carly M Bliss^{1,4}, Alan L Parker^{1,4}

1. Division of Cancer & Genetics, Cardiff University
2. Division of Infection & Immunity, Cardiff University
3. Cwm Taf Morgannwg University Health Board
4. Systems Immunity University Research Institute (SIURI), Cardiff University

Cell Talk: Adipocyte Derived Exosomes Promote Cell Invasion and Challenge Paclitaxel Efficacy in Ovarian Cancer

Michael Ellis Williams¹, David Howard¹, Claire Donnelly¹, Fereshteh Izadi¹, Jezabel Garcia Parra¹, Megan Pugh¹, Kadie Edwards¹, Kerryn Lutchman-Sigh², Sadie Jones³, Lavinia Margarit^{1,4}, Lewis Francis¹, R Steven Conlan¹, Francesca Taraballi⁵, Deyarina Gonzalez¹

1. Swansea University Medical School, Swansea University
2. Department of Gynaecology Oncology, Swansea Bay University Health Board.
3. Department of Obstetrics and Gynaecology, Cardiff and Vale University Health Board
4. Department of Obstetrics and Gynaecology, Cwm Taf Morgannwg University Health Board.
5. Center for Musculoskeletal Regeneration, Houston Methodist Research Institute, Houston

Preclinical Advances in Ovarian Cancer Therapy: Development of an Antibody-Drug Conjugate Targeting RAGE

Jezabel Garcia-Parra¹, Claire Donnelly¹, Lilianna Ordonez¹, Melanie Boudaud², Belen Pan-Castillo¹, David Howard¹, Emenike Onyido¹, Kate Murphy³, Gilian Seaton⁴, Richard Clarkson⁴, Kerryn Lutchman-Singh⁵, Sadie Jones⁶, Lavinia Margarit⁷, Nadia Alfaidy², R Steve Conlan¹, Deyarina Gonzalez¹

1. Medical School, Swansea University
2. Interdisciplinary Research Institute of Grenoble, University Grenoble Alpes
3. Department of Cellular Pathology, Swansea Bay University Health Board
4. Cardiff University School of Biosciences, Cardiff University
5. Department of Gynaecology Oncology, Swansea Bay University Health Board
6. Department of Obstetrics and Gynaecology, Cardiff and Vale University Health Board
7. Department of Obstetrics and Gynaecology, Cwm Taf Morgannwg University Health Board

Investigation of Adenovirus Species D Serotypes as Novel Oncolytic Vectors

Rebecca Wallace¹, Emily Bates¹, Rosie Mundy¹, Carly Bliss¹, Alan Parker¹

1. Division of Cancer & Genetics, Cardiff University School of Medicine

Investigating the Role of Exosomes in Antibody-Drug Conjugate Therapy: A Preliminary Study

Saoirse Wilson^{1,2}, Claire Donnelly¹, David Howard¹, Kadie Edwards¹, Caitlin Rees¹, Abdul Nagi¹, Lewis Francis¹, R Steve Conlan¹, Deyarina Gonzalez¹

1. Medical School, Swansea University
2. Biomedical Sciences, Cardiff University

Development of an Oncolytic Adenovirus platform expressing a suicide transgene to target Pancreatic Ductal Adenocarcinoma

Luned M. Badder¹, Emily Bates¹, Catherine Hogan², Alan L. Parker¹

1. Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, Wales
2. European Cancer Stem Cell Research Institute (ECSCRI), School of Biosciences, Cardiff University, Wales

The Generation of an Organoid Toolkit

Stephanie Burnell¹, Chloe Harris¹, Lorenzo Capitani¹, Stefan Milutinovic¹, Carina Owen¹, Julia Grimstead², Sara Seifan², Duncan Baird², Luned Badder², Alan Parker², Kasope Wolffs^{1,3}, Fiona Morgan³, Paola Foulkes³, Andrew Godkin^{1,4}, Awen Gallimore¹

1. Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
2. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
3. Wales Cancer Biobank, UHW Main Building, Heath Park, Cardiff, CF14 4XN, UK
4. Department of Gastroenterology and Hepatology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK

The Urinary Microbiome Shifts in Women with Breast Cancer

Nur Aimi Aliah Zainurin¹, Matthew Hegarty¹, Dimitra Ivanova¹, Tim Gate³, Helen Tench⁴, Mandana Pennick², Luis A. J. Mur¹

1. Department of Life Sciences, Aberystwyth University,
2. Glan Clwyd Hospital, Betsi Cadwaladr University Health Board,
3. Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board,
4. Bronllais General Hospital, Hywel Dda University Health Board

Radiotherapy

Addressing national barriers for UK clinical oncology trainees in radiotherapy research

Shannon Rowlands¹, Richard Adams^{2,3}, Jonathan Helbrow¹, Daniah Thomas¹, Sarah Gwynne¹

1. South West Wales Cancer Centre, Swansea
2. Centre for Trials Research, Cardiff University, Cardiff
3. Velindre Cancer Centre, Cardiff

Exchange time from time-dependent diffusion-weighted MRI as a potential biomarker for treatment response in human brain metastasis

Elise Gwyther¹, Sahar Iqbal², James Powell², Jennifer Golten², Beat Jucker³, Maëliiss Jallais¹, Derek Jones¹, Chantal Tax^{1,5}, Marco Palombo^{1,4}

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom
2. Velindre Cancer Center, Cardiff, United Kingdom
3. Glaxosmithkline, Pennsylvania, United States
4. School of Computer Science and Informatics, Cardiff University, Cardiff, United Kingdom
5. University Medical Center Utrecht, Utrecht, Netherlands

Cardiff University School of Medicine MRC equipment bid (2025): How a Small Animal Radiation Research Platform (SARRP) will enhance translational science across Wales and the South-West.

Paul Shaw¹, Stephen Paisey², Ian Brewis³

1. Department of Clinical Oncology, Velindre University NHS Trust
2. PETIC, University Hospital of Wales and Cardiff University
3. School of Medicine, College of Biomedical and Life Sciences, Cardiff University

Benchmarking and quality assurance of a new prostate cancer brachytherapy service: prospective data collection and 2 year patient reported outcome measures

Jake Tanguay¹, Jane Powell², Alice Roebuck³, Emily Renninson¹, Donna Llewlyn⁴, Katie Hook⁵, Nachi Palaniappan¹

1. Clinical Oncology, Velindre Cancer Centre
2. Radiotherapy Physics, Velindre Cancer Centre
3. Data and Insights, Velindre Cancer Centre
4. Radiotherapy, Velindre Cancer Centre
5. Urology CNS, Velindre Cancer Centre

Advanced MRI techniques highlight distinct vascular characteristic across Glioma subtypes

Eleonora Patitucci¹, Stefano Zappalà², James Powell³, Najmus Sahar Iqbal³, Richard Wise^{4,5}, Michael Germuska M^{6,7}

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, UK
2. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Computer Science and Informatics, Cardiff University, Cardiff, UK
3. Department of Oncology, Velindre University NHS Trust, Cardiff, UK
4. Department of Neurosciences, Imaging, and Clinical Sciences, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy

5. Institute for Advanced Biomedical Technologies, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy
6. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Physics and Astronomy, Cardiff University, Cardiff, UK
7. Department of Radiology, University of California Davis Medical Center, Sacramento, CA, United States of America

A comparison of gas-free MRI methods for CMRO2 quantification in primary brain tumour

Stefano Zappalà¹, Eleonora Patitucci², James Powell³, Sahar Iqbal³, Fabian Küppers⁴, Jon Shah⁴, Richard Wise⁵, Michael Germuska⁶

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Computer Science and Informatics, Cardiff University
2. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University
3. Department of Oncology, Velindre University NHS Trust
4. Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich
5. Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti-Pescara
6. Department of Radiology, University of California Davis Medical Center

Cancer clinical trials

Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia

Dolce Advani¹, Joanna Canham¹, Angela Casbard¹, Sylvie D Freeman², Nicola Potter, PhD³, Abin Thomas¹, Amanda Gilkes, PhD⁴, Sean Johnson¹, Lucy Marsh¹, Jane Leahy⁵, Hayley Timmins¹, Richard Dillon, MA³, Steven Knapper, MRCP, FRCPath, DM⁶

1. Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
2. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
3. Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
4. Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, United Kingdom
5. Private affiliation, PPI Representative, London, United Kingdom
6. Cardiff University School of Medicine, Cardiff, United Kingdom

Collecting patient outcome data across Wales for medicines accessed via the All Wales Therapeutics and Toxicology Centre (AWTTC) One Wales Medicines process

Rosie Spears^{1,2}, Rachel Jonas^{1,2}, Gail Woodland^{1,2}, Craig Barrington³

1. All Wales Therapeutics and Toxicology Centre
2. Cardiff and Vale University Health Board
3. Department of Oncology, Swansea Bay University Health Board

Emma Williams and her team of research nurses and clinical colleagues are helping to encourage more nurses to get more involved in research

Emma Williams¹, Katja Williams¹, Jenni Davies¹, Louise Jenkins¹, Bethan Ingram², Sarah Doherty³, Emily John⁴, Faye Blackborrow⁵

1. Clinical Research Group Cardiff
2. Senior Nurse
3. Advance Nursed Practitioner, Bone Marrow Transplant
4. CART Clinical Nurse Specialist
5. Advance Nursed Practitioner

Change of study design during the feasibility part of a non-randomised multicentre study (QuicDNA) to roll out routine ctDNA testing for lung cancer in NHS Wales

Muhammad Riaz¹, Angela Casbard¹, Georgina Gardner¹, Margherita Carucci¹, Sian Morgan³, Rachel Dodds³, Richard Adams¹, Magdalena Meissner²

1. Centre for Trials Research, College of Biomedical & Life Sciences Cardiff University
2. Division of Cancer and Genomics, Cardiff University and Velindre Cancer Centre
3. All Wales Medical Genomics Services, NHS, Wales

Evolving from Phase II into Academia's Largest Head and Neck Cancer Trial

Christie Heiberg¹, Lisette Nixon¹, Christopher Hurt², Joanna Canham¹, Ceri Frayne¹, Charlotte Martin¹, Sean Johnson¹, Mererid Evans¹, Terry M Jones³

1. Cardiff University
2. University of Southampton
3. Liverpool University

The Evolution of GastroSCOPE - proposed as the first UK-led trial of high-dose radiotherapy for inoperable gastric cancer

Amy Case^{1,2}, Elena Brogdan³, Lisette Nixon³, Angela Casbard³, Owen Nicholas^{1,2}, Kieran Foley^{4,5,6}, Gina Brown⁷, David Watkins¹, Tom Crosby⁶, Richard Adams^{3,6}, Deborah Fitzsimmons², Ganesh Radhakrishna⁸, David Chuter¹⁰, Sue Campbell¹⁰, Colin Askill, Christopher M. Jones⁹, Christopher J Peters⁷, Sarah Gwynne^{1,2}

1. South West Wales Cancer Centre, Swansea Bay University Health Board
2. Swansea University
3. Centre for Trials Research, Cardiff University
4. Division of Cancer & Genetics, School of Medicine, Cardiff University
5. Cwm Taf Morgannwg University Health Board
6. Velindre Cancer Centre, Velindre University NHS Trust
7. Imperial College London
8. The Christie NHS Foundation Trust
9. Department of Oncology, University of Cambridge
10. Private Affiliation, Patient and Public Involvement Representative

Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study (NCT05655078)

P. Shaw¹, A. Gosling², K. Durno³, C. Clarke⁴, C. Gardiner⁵, C. Hiley^{2,6}, P. Patrick⁶, N. Counsell^{2,6}

1. Dept Clinical Oncology, VUNHST
2. UCL Hospital, London
3. Barking, Havering & Redbridge University Hospitals NHS Trust, London, UK
4. UCL, London, UK
5. University Sheffield, Sheffield, UK
6. UCL Cancer Institute, London UK

Embedding research in NHS organisation systems: Survey results of clinical ownership, support and integration of clinical trials in NHS business.

Christopher Scrase^{1,2,3}, Carla Potheary¹, Carys Thomas⁴, Nicola Williams⁵, Tom Crosby^{1,6}

1. NHS Wales Executive
2. Bangor University
3. Department of Oncology, Ysbyty Glan Clwyd, Betsi Cadwaladr University Health Board
4. Welsh Government
5. Health and Care Research Wales
6. Velindre Cancer Centre

Piloting a standardised variable syntax in a new skin cancer trial: SCC-AFTER

Ceri Frayne¹, Casbard A¹, Nixon L¹, Porter C¹, White A¹

1. Centre for Trials Research, Cardiff University

Application of a practical method for eliciting prior beliefs about cancer survival in a phase 3 randomised trial of radiotherapy for patients with skin cancer

Ms Angela Casbard¹, Dr Emilia Peleva², Dr Rachel Abbott³, Dr Marisol Vazquez³, Professor Catherine Harwood², Malavika Babu¹, Professor Agata Rembielak^{4,5}, Mr Lincoln Tarirai Mahachi¹, Dr Jerry Marsden⁶

1. Centre for Trials Research, Cardiff University
2. Department of Dermatology, Barts Health NHS Trust
3. Cardiff and Vale University Health Board
4. The Christie NHS Foundation Trust
5. The University of Manchester
6. University Hospitals Birmingham NHS Foundation Trust

Management of a Complex Dataset

Charlotte Martin¹, Ceri Frayne¹, Christie Heiberg¹, Christopher Hurt², Sean Johnson¹, Joanna Canham¹, Lisette Nixon¹, Terry M Jones³, Mererid Evans¹

1. Cardiff University
2. University of Southampton
3. Liverpool University

Streamlining Cancer Clinical Trial Setup: Key Milestones, Facilitator Roles, and Strategies for Accelerated Timelines

Claire Bryant¹

1. Research and Development, Velindre University NHS Trust

Palliative and supportive oncology

Barriers to and facilitators of access, acceptability and adherence to cancer prehabilitation: a mixed methods systematic review

Dr Tessa Watts¹, Dr Nicholas Courtier¹, Dr Sarah Fry¹, Dr Nichola Gale¹, Elizabeth Gillen¹, Dr Grace McCutchan², Manasi Patil¹, Tracy Rees³, Dr Dominic Roche¹, Dr Sally Wheelwright⁴, Professor Emirata Jane Hopkinson¹

1. School of Healthcare Science, Cardiff University
2. Division of Population Medicine, Cardiff University
3. Velindre Oncology Academy, Velindre University NHS Trust
4. Brighton and Sussex Medical School, University of Sussex

A service improvement project assessing the current practice for discharge letter documentation within a specialist oncology hospital.

Dr. Caitlin Cahill¹, Professor Nikki Pease²

1. Junior Clinical Fellow in Palliative Medicine, Velindre University NHS Trust
2. Professor of Palliative Medicine, Velindre University NHS Trust

Nurses' experiences of caring for people with cancer in a general hospital setting

Karen Gillespie¹, Jeorgia Greenfield¹, Dr Tessa Watts²

1. Acute Oncology, Cardiff and Vale UHB
2. School of Healthcare Sciences, Cardiff University

Implementation of cancer-specific Holistic Needs Assessment (HNA) tools in clinical practice and their applicability to the brain tumour population; systematic review and narrative synthesis.

Sivell S¹, Mann M^{1,2}, Hamilton T³, Baddeley E¹, Byrne A⁴, Retzer A⁵

1. Marie Curie Research Centre, Division of Population Medicine, Cardiff University
2. Specialist Unit for Review Evidence, Cardiff University
3. Palliative Care, Aneurin Bevan University Health Board
4. Velindre University NHS Trust
5. Centre for Patient-Reported Outcomes Research & NIHR Applied Research Collaboration West Midlands, Institute of Applied Health Research, University of Birmingham

Informing the definition of Future Care Planning within end of life care: a scoping review of the literature.

Sivell S¹, Mann M^{1,2}, Hackett R³, Harding E⁴, Taubert⁵

1. Marie Curie Research Centre, Division of Population Medicine, School of Medicine, Cardiff University
2. Specialist Unity for Review Evidence, Cardiff University
3. Velindre University NHS Trust and City Hospice Palliative Care Team, Cardiff
4. Velindre University NHS Trust, Wales
5. School of Medicine, Cardiff University

Population health-based cancer prevention and early diagnosis

A Third Sector Campaign to Increase Symptom Awareness of Oesophageal and Stomach Cancer in Wales

Madeleine Young¹, Stephanie Jones², Hasan Habibi³, Catrin Hallert¹, Greg Pycroft¹, Lowri Griffiths¹

1. Tenovus Cancer Care
2. Bath University
3. Cardiff and Vale Health Board

Current Landscape of Drug approvals for Genitourinary (GU) Cancers in North America and Europe.

Jose C. Tapia¹, Javier Gavira², Diana Matthews¹, Matteo Santoni³, Matthew Young⁴, Louis Blondel⁵, Ronan Flippot², Ricky Frazer¹, Georgja Anguera⁶, Pablo Maroto⁶

1. Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, Wales, United Kingdom
2. Medical Oncology Department, Institut Gustave Roussy, Paris Saclay University, Villejuif, France

3. Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy
4. Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom
5. Institut Gustave Roussy, Paris Saclay University, Villejuif, France
6. Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

Disparities in Urothelial Carcinoma (UC) Drug Approval: Contrasting North America and Europe

Jose C. Tapia¹, Javier Gavira², Diana Matthews¹, Matteo Santoni³, Matthew Young⁴, Louis Blondel⁵, Ronan Flippot², Ricky Frazer¹, Georgia Anguera⁶, Pablo Maroto⁶

1. Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, Wales, United Kingdom
2. Medical Oncology Department, Institut Gustave Roussy, Paris Saclay University, Villejuif, France
3. Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy
4. Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom
5. Gustave Roussy, clinical pharmacy department, Villejuif, France
6. Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

The Epidemiology of Cancer and Cardiovascular Disease Diagnosis in the UK

Caitlin Partridge¹, James Rafferty¹, Keith R Abrams², Rhiannon K Owen¹

1. Department of Health Data Science, Swansea University
2. Department of Statistics, University of Warwick

How can we equitably support people if self-sampling becomes a part of cervical screening? Foundations for a decision Support intervention to support Choice in Cervical screening modality (SUCCEED)

Dr Eleanor Clarke¹, Dr Denitza Williams¹, Dr Kate J Lifford¹, Lindsay Haywood², Prof Fiona Wood¹, Prof Jo Waller³, Prof Adrian Edwards¹, Dr Natalie Joseph-Williams¹, Dr Caroline Evans², Gareth Powell⁴, Dr Rhiannon Phillips⁵, Prof Andrew Carson Stevens¹, Dr Katie Walbeoff⁴, Dr Ardiana Gjini⁶, Prof Kate Brain¹

1. Cardiff University
2. PPI Partner
3. Queen Mary University of London
4. Public Health Wales
5. Cardiff Metropolitan University
6. Hywel Dda Health Board

PROSTAD: Development of a Model Prostate Cancer Diagnostic Pathway

Savita Shanbhag¹, Rachel Gemine², Stephen Farrington³, Yeung Ng⁴, Chris Hopkins³

1. Medical Directorate, Hywel Dda University Health Board
2. NHS Wales Joint Commissioning Committee
3. TriTech Institute & Innovation, Hywel Dda University Health Board
4. Urology Department, Hywel Dda University Health Board

Acceptability and accessibility of using a peer-led WhatsApp group for sharing prostate cancer risk information: protocol for a pilot study for proof of concept

Dr Sarah Fry¹, Dr Shancang Li², Dr Georgios Theodorakopoulos², Dr Nicholas Courtier¹, Dr Harriet Quinn-Scoggins³

1. School of Healthcare Sciences, Cardiff University
2. School of Computer Science and Informatics, Cardiff University
3. School of Medicine, Cardiff University

Insights, challenges and opportunities for cancer clinical care, workforce, innovation and research in Wales from the HIWBRIS Study (Healthcare Innovation, staff Wellbeing and Burnout: Researching Interactions and Solutions; IRAS 346499)

Dr Mick Button¹, Jennet Holmes², Dr Tom Howson³, Dr Roderick Thomas⁴, Professor Nick Rich⁴

1. Medical Directorate, Velindre Cancer Services, Velindre University NHS Trust
2. Innovation Lead, Velindre University NHS Trust
3. Bevan Commission
4. School of Management, Swansea University

Inclusion in cancer prehabilitation: Qualitative research to explore access and adherence to cancer prehabilitation in Wales

Alexandra Mitchell¹, Manasi Patil¹, Sherina Lowe¹, Akhilesh Ramachandran¹, Tessa Watts¹, Jane Hopkinson^{1,2}

1. School of Healthcare Sciences, Cardiff University
2. On behalf of the NIHR I-Prehab Project research team

Understanding the barriers and facilitators affecting the use of remote consultations among marginalised communities: a mixed-methods systematic review

Julia Hiscock¹, Grace McCutchan², Kate Brain², Richard Neal³

1. North Wales Centre for Primary Care Research, Bangor University
2. Cardiff University
3. University of Exeter

Could we utilise 'one stop shop' clinics to help ensure our cancer patients meet endoscopy waiting targets?

Jennifer Waterman¹, Michael Beddard², Heuy Yi Chong²

1. University Hospital of Wales, Cardiff and Vale University Health Board
2. Centre for Healthcare Evaluation, Device Assessment and Research (CEDAR), Cardiff and Vale University Health Board

CRT Together Improving the Cancer Journey programme: 1-year evaluation findings of a referral service addressing the non-clinical needs of people affected by cancer

Ann Broadway¹, Alice Timbrell²

1. Coalfields Regeneration Trust
2. Urban Foresight

Emergency Cancer Diagnoses - Impact on Healthcare Staff: Initial Analysis

Karen Wingfield^{1,2}, Dr Sarah Fry³, Emeritus Professor Daniel Kelly⁴

1. PhD Student School of Healthcare Sciences, Cardiff University
2. Macmillan Acute Oncology CNS, Cwm Taf Morgannwg UHB
3. School of Healthcare Sciences, Cardiff University
4. Emeritus Professor, School of Healthcare Sciences, Cardiff University

How might the provision of smoking cessation services be adapted to improve uptake and success for people in low socioeconomic groups? A qualitative study (PROCESS Study)

Dr Pamela Smith, PhD¹, Lucia Dahlby, MScR², Dr Evgeniya Plotnikova, PhD², Dr Rebecca-Bell Williams, PhD³, Rebecca Thorley³, Dr Fiona Dobbie, PhD², Dr Tessa Langley, PhD³, Dr Ilze Bogdanovica, PhD³, Prof Kate Brain, PhD¹, Prof Rachael Murray, PhD³, Dr Leah Jayes, PhD⁴

1. Cardiff University, Wales
2. University of Edinburgh, Scotland
3. The University of Nottingham, England
4. Nottingham Trent University, England

Using a behavioural science approach to raise awareness of breast screening.

Naomi Morgan¹, Charlotte Cullum¹, Rhian Meaden¹

1. Cwm Taf Morgannwg University Health Board

Preparing the public for equitable and informed implementation of Multi-Cancer Early Detection (MCED) blood tests

Delyth Price¹, Richard Adams², Kate Brain¹, Julie Hepburn³, Rashmi Kumar³, Laura Marlow⁴, Uju Ogbonna¹, Fiona Wood¹, Harriet Quinn-Scoggins¹

1. Division of Population Medicine, Cardiff University
2. Centre for Trials Research, Cardiff University
3. Lay Representative
4. Centre for Cancer Prevention, Screening and Early Diagnosis, Queen Mary University of London